03/02/2026
A new stem cell-based approach for spinal cord injury is moving into early-stage human testing, with the goal of helping people regain lost movement after paralysis.
The program centers on an “off-the-shelf” regenerative cell product made from allogeneic induced pluripotent stem cells (iPSCs) that are guided into subtype-specific neural progenitor cells. The idea is to deliver these lab-produced cells directly to the injury site, where they may integrate with damaged spinal tissue and support repair of disrupted nerve pathways.
According to the company announcement, regulatory clearance for a registrational Phase I trial was granted by both National Medical Products Administration and the U.S. Food and Drug Administration, positioning this as a notable first for this specific “subtype-specific neural progenitor” strategy in spinal cord injury.
In Guangzhou, an early report on trial launch and initial dosing described the start of the Phase I study targeting spinal cord injury and noted no immediate surgical or perioperative complications in the first treated subject, which is an important early safety signal for a therapy delivered directly into the spinal cord.
The clinical study described in the company release is led by The Third Affiliated Hospital of Sun Yat-sen University, which the announcement describes as a major center for spinal cord injury care.
Spinal cord injury remains a major unmet medical need worldwide. The same release estimates more than 15 million people living with spinal cord injury globally, including roughly 3 million in China and about 300,000 in the United States, with large numbers of new acute or subacute cases reported each year.
The broader scientific rationale matches what has been seen in advanced preclinical research: iPSC-derived spinal neural progenitor cells can differentiate into relevant neuron types, integrate with host neural circuits, help shift the injury environment toward neuroprotective responses, and support axona